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As of February 2012, 50 circulating recombinant forms (CRFs) have been reported for HIV-1 while one CRF for HIV-2. Also
according to HIV sequence compendium 2011, the HIV sequence database is replete with 414,398 sequences. The fact that there
are CRFs, which are an amalgamation of sequences derived from six or more subtypes (CRF27 cpx (cpx refers to complex) is a
mosaic with sequences from 6 diﬀerent subtypes besides an unclassiﬁed fragment), serves as a testimony to the continual divergent
evolution of the virus with its approximate 1% per year rate of evolution, and this phenomena per se poses tremendous challenge
for vaccine development against HIV/AIDS, a devastating disease that has killed 1.8 million patients in 2010. Here, we explore the
interaction between HIV-1 and host genetic variation in the context of HIV/AIDS and antiretroviral therapy response.
1.Introduction
The evidence for HIV to be the causative agent of AIDS was
documented way back in 1983, and, hitherto, the dreadful
HIV remains unconquered [1]. As of 2010, 34 million people
are living with HIV infections and 2.7 million people have
been newly infected in that year alone [2]. This alarming
statistics have accelerated much research into the biology of
HIV,seekingclueson“Achillesheel”soastocurtailitsspread
and eventually to eradicate it.
2.HIV-1OriginandDiversity
HIV-1 and HIV-2 cause AIDS, and HIV-1, with its tremen-
dous diversity, outwits HIV-2 by its ability to inﬂict a more
virulent form of the disease and has global distribution [3].
Both viruses originated in Africa, and viral zoonosis resulted
in the rampant AIDS epidemic. Simian immunodeﬁciency
virus (SIV) from chimpanzees (SIVCPZ) is closely related
to HIV-1, while SIV from sooty mangabeys (SIVSM)f o r m s
the closest to HIV-2 [4, 5]. HIV-1 viruses fall under three
main phylogenetic lineages, namely, M (Main), O (outlier),
and N (non-M/non-O), all considered to have originated
from chimpanzees dwelling in the eastern equatorial forests
of Cameroon, West Central Africa, with O group viruses
throughagorillaintermediate[6–8].SIVinfectedPantroglo-
dytes troglodytes (Ptt) chimpanzees gave rise, through cross-
speciestransmission,toHIV-1groupsMandNviruseswhile
SIV-infected gorillas (Gorilla gorilla; SIVgor), which them-
selves contracted infection originally from chimpanzees,
gave rise to formation of group O HIV-1 viruses. Recently,
a variant of HIV-1 group O virus has been detected—P
group—which resembles more closely to SIVgor than O
group virus, in individuals of Cameroon origin [9, 10].
Studies have estimated the timing for origin of each lineage
of HIV—HIV-1 group M, O, and N at 1931 (1915–1941),
1920 (1890–1940), and 1963 (1948–1977), respectively [11–
13]. HIV-2 viruses are considered to have originated around
1930s [13].
Group M HIV-1 viruses are further subdivided into nine
major subtypes, namely, A-D, F-H, J, and K. Sub-subtypes
have been reported for clade A (A1 and A2) and F (F1 and
F2) viruses. Group M also includes circulating recombinant
forms (CRFs). Figures 1(a) and 1(b) illustrate global dis-
tribution of HIV subtypes and most common CRFs, respec-
tively. Circulating recombinant forms arise as a result of2 Advances in Virology
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Figure 1: (a) Global distribution of HIV-1 (nonrecombinants) sequences. (b) Global distribution of recombinant HIV-1 sequences. Source:
HIV databases [14].
recombination between any of the subtypes and/or CRFs
leadingtotheformationofCRFssuchasAE,AG,AB,DF,BC,
CD, and other complex forms. Figure 2 provides a schematic
representation of composition of 50CRFs that have been
identiﬁed hitherto [14]. The subtypes and CRFs attest to the
geneticdiversityofHIV-1.TheseMgroupvirusescausemost
of the HIV-1 infections, accounting for the current AIDS
pandemic. Circulating recombinant forms account for about
10% of all HIV infections [8], and the proportion might
increase in future. Diﬀerent subtypes among HIV-1 viruses
impactdiseaseprogressiondiﬀerently[15]andmayalsohave
diﬀerential sensitivity to antiretroviral therapy (ART) drugs
[16]. Individuals infected with subtype D viruses are known
to experience rapid disease progression [17], whereas those
infected with subtype C undergo slow disease progression
[18]. During the course of HIV-1 infection, strains that
utilize coreceptor CXCR4, emerge during late stages of in-
fection in contrast to CCR5 utilizing M tropic strains that
are seen during early stages of infection. The strains that
use CXCR4 are known to exhibit cytopathic eﬀect in vitro
[19]. However, this observation might be an in vitro artifact
since little cytopathic eﬀects were noticed in vivo [20]. There
is diﬀerential usage of CXCR4 coreceptor among subtype C
and D viruses, with subtype C viruses rarely switching to
CXCR4 usage and subtype D viruses utilizing CXCR4
receptor earlier and frequently, and this, alongwith other
factors like genetic variation in long terminal repeat (LTR)
promoter, might account for their varied impact on disease
progression [8, 21–24]. The promoter/enhancer activities of
LTRs of subtype C viruses were shown to be higher than that
o fo t h e rs u b t y p e sA ,B ,D ,E ,a n dG[ 23], and subtle dif-
ferences in promoter activity of LTRs might aﬀect HIV
replication kinetics substantially [24, 25]. The intrasubtype
diversity is substantial among diﬀerent subtypes of HIV-1.
The protein sequence diversity among subtypes of HIV-1
g r o u pMv i r u s e sf o rG a g ,P o l ,a n dE n va r er e p o r t e dt o
be 15%, 10%, and 24%, respectively [26]. Gag-30 position
is phylogenetically important. The sequences of SIVCPZPtt,
fromwhichHIV-1originated,aremarkedbypresenceofMet
at Gag-30. In contrast, the ancestors of all the three HIV-1
groups (M, O, and N) are marked by sequences that contain
Arg at Gag-30, highlighting potential host-species-speciﬁc
adaptation [27]. Understanding HIV evolution and the role
that the host plays in mediating it and controlling infection
will undoubtedly help to determine the eﬀective approaches
to combat HIV/AIDS.
3.Degreeof HIV-1Variability
HIV-1, with its RNA genome, demonstrates signiﬁcant
genetic diversity due its high mutation rate. It has diversiﬁed
itself to such an extent, through its ability to form “cloud”
of variants or quasispecies, that there is no single wild-type
strain. In vitro data have shown that RNA viruses generate
nonhomogeneous genetic clones that are closely related but
genetically diverse, which are known as quasispecies. This
phenomenon, which aids viruses to persist in their host,
possibly causing disease, is observed in other RNA viruses
such as hepatitis C and inﬂuenza virus as well [28, 29].
The reverse transcriptase (RT) of HIV-1, which lacks 3 -5 
exonucleolytic proof-reading function, misincorporates 1 in
6900 and 1 in 5900 nucleotides polymerized on the RNA and
DNA template, respectively, and hence accounts for larger
proportion of mutations seen in HIV-1 [30]. It has been esti-
mated that, after a single round of HIV-1 replication, underAdvances in Virology 3
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Figure 2: Schematic representation of composition of HIV-1 CRFs.4 Advances in Virology
the assumption of absence of selection pressure, the resulting
progeny viruses will have substitution, frameshift and dele-
tions at 24%, 4%, and 2%, respectively [31]. It is interesting
to note that 80% of heterosexual-mediated HIV-1 infections
are due to productive infection by a single HIV-1 virion [32–
34]. HIV-1 evolves at about 1% per year [35]. Given that
HIV-1 faces selection pressures, a gamut of mutations has
shaped its genome since its origin, which in turn, ensures its
virulence at population level [36, 37], despite the fact that
certain mutations in its conserved region impacts its ﬁtness
negatively [38]. Further, a recent study that utilized phylo-
genetic comparative approach revealed that viral genotype,
as against the host genetic proﬁle, largely determines the
HIV set-point viral load and hence the virulence [39]. A
schematic sketch of error-causing machinery involved in
HIV-1 mutagenesis and a gamut of selection pressure acting
on HIV-1 are provided in Figures 3(a) and 3(b),r e s p e c t i v e l y .
3.1. Ultra-Deep Sequencing Reveals Vastness of HIV-1 Vari-
ability. With the emergence of new pyrosequencing tech-
nology, HIV-1 viral quasispecies are now more rapidly and
accurately sequenced and analyzed. Mutation spectra of
HIV-1 quasispecies are wide, and traditional sequencing
methodologiesarelimitedintheirabilitytocaptureminority
variants [40]. Next generation sequencing (NGS) method-
ologies have made it possible to obtain high-throughput
sequence data at an unprecedented pace and coverage (e.g.,
pyrosequencingusingGSFLX+systempermitcharacterizing
upto1000bpreadlengthwith1,000,000readsperrunatrun
time of 23 hours and consensus accuracy of 99.997%) [41,
42] and are being employed to decipher HIV-1 evolutionary
trajectories [34, 43]. Recently, Liang et al. [44] used 454
pyrosequencingtechnologyandsangerclone-basedsequenc-
ing to assess the genetic diversity of HIV-1 gag and it was
determined that pyrosequencing detected almost four times
more variation in gag than sanger sequencing. Ultra-deep
sequence sets of HIV-1 allow for deciphering CTL escape
variants that are not discernable with the sequences obtained
through conventional sequencing strategies [34, 44]. While
single genome amplication (SGA) is superior to standard
genotyping method [45], ultra-deep sequencing methods
oﬀer highest sensitivity to date in relation to those conven-
tional methods as it can detect minor viral variants that
comprise lower than 1% of the population. This highest level
of sensitivity by ultra-deep sequencing also allows for iden-
tifying low-abundance drug resistant variants [40], with
potentialtointerferewithARToutcome.NotonlyNGStech-
niques are used to gain insights into the sequence of the viral
genome with greater depth, it has also been recently utilized
to examine viral diversity after therapy. For example, a study
that used deep sequencing technology to examine escape
mutations in the V3 loop of HIV-1 that arise as a result of
selection by CCR5 antagonist (vicriviroc, a drug that inhibits
HIV-1 entry) therapy indicated signiﬁcantly higher sequence
heterogeneity [43]. Knowledge on nature of HIV-1 quasis-
pecies gained through ultra-deep sequencing technologies
can aid in progressing HIV research and managing HIV/
AIDS clinically better. Finally, with advanced whole genome
sequencingtechnologies, theability to correlategenomepro-
ﬁle of HIV with that of patients could lead to comprehensive
understanding of disease process and eﬀective interventions.
3.2. Factors Driving HIV-1 Variability
(a) Inherent Property of the Reverse Transcriptase (RT) and
Recombination. The generation of diverse variants in HIV-1
can be attributed mainly to its low-ﬁdelity RT enzyme,
leading to error-prone reverse transcription [30]. RT also
accounts for genomic heterogeneity in progeny viruses
through its role in recombination. Besides RT, which ac-
countsforlargerproportionofmutationsobservedinHIV-1,
the host RNA pol II involved in transcription of proviral
DNA can also contribute to mutations, albeit minimally. A
study has indicated contribution of cellular RNA pol II to be
less than 3% of retroviral frame-shift mutations [46].
HIV-1, with documented dual and triple infections in
patients [47, 48], can substantially drive production of viral
quasispecies that are endowed with superior ﬁtness through
the process of genetic recombination, a time-tested evolu-
tionary strategy to thrive in a changing environment. With
an average of 1.38 × 10
−4 recombination events/adjacent
sites/generation in vivo [49], HIV-1 ensures its ability to
enrich both diversity and ﬁtness. In HIV-1, recombination
in genomic regions with high selection pressure, either in the
form of host immune response or ART drugs, could lead to
selection of more ﬁt genomes, while, in regions under neg-
ligible selection, recombination can enhance diversity [50].
HIV-1-infected commercial sex workers in Nairobi, Kenya,
were shown to harbor high proportion of recombinant HIV-
1v i r u s e s[ 51, 52]. Recombinants between highly similar
HIV-1 strains are formed at highest frequencies while that
betweenverydistantHIV-1strainsoccuratverylowfrequen-
cies [53]. Genetic recombination between HIV-1 and HIV-2
is also a potential possibility [54].
(b) Swift Turnover Rates of HIV-1 In Vivo. HIV-1 virions
are produced and cleared at extremely rapid pace. HIV-1
turnover is high at 1011 virions and 108 infected cells per day
[45]. Studies have estimated that free HIV-1 viral particles
have an half-life of less than 6 hours, while the productively
infected cells possess an half-life of about 1day [55]. This
rapid turnover has been considered as the major factor
underlying pathogenesis of HIV/AIDS, wherein there is
greater destruction of CD4+ Th e l p e rl y m p h o c y t e s .
(c) Drugs of ART Drive Changes in HIV Genetic Makeup.
Antiretroviral drugs as well as associated drug resistance
mutations could inﬂuence in vivo HIV-1 mutation rates. The
drug 3 -azido-3 -deoxythymidine (AZT) can enhance HIV-1
mutation rate by a factor of seven per round of replication,
and HIV-1 variants harbouring AZT resistant RT can incur
higher mutation rate as much as threefold relative to wild-
type RT bearing HIV-1 [56]. The V106A is a nevirapine
(nonnucleoside RT inhibitor) resistance mutation that has
been consistently shown to aﬀect viral ﬁtness severely [57].
Mutations associated with HIV-1 drug resistance could beAdvances in Virology 5
HIV-1 variation
exonucleolytic proofreading activity and carries out error-
prone reverse transcription)
mutation, though minimally, while performing
transcription of proviral DNA)
host enzyme causes G-to-A
hypermutation)
Reverse transcriptase (this viral enzyme lacks 3-5
Host RNA pol II (this host enzyme introduces APOBEC3 protein (this
(a)
HIV-1
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Speciﬁc antiviral host factor
(e.g., TRIM5α and APOBEC3
(b)
Figure 3: (a) Error-causing machinery involved in HIV-1 mutagenesis. (b) A schematic sketch of selection pressures acting on HIV-1.
Note: ART drugs block is shown in grey colour to diﬀerentiate from others, as such drugs exert inﬂuence over HIV-1 indirectly in patients
undergoing ART.
presentindrug-na¨ ıvepatientsatlowfrequencies,ofteninter-
fering with outcome of ART [58]. Metzner et al. [59]h a v e
reported occurrence of M184V (RT) and L90M (protease)
mutations as minority populations in patients undergoing
structured treatment interruptions. A comprehensive list of
ART drug-associated mutations is being maintained in Stan-
ford HIV Drug Resistance Database [60]. Further discussion
on ART drugs is covered in Section 6.
(d) Selective Immune Pressures from Host. There is heteroge-
neity in disease progression among HIV-1-infected patients.
Host genetic variants have been shown to account for at
least 15% of the observed diﬀerences in disease progression
[61].Humanleukocyteantigen(HLA)system,residinginthe
sixth chromosome, is the most polymorphic loci in human
genome and this extensive polymorphism is the result of
evolving with millions of pathogens that the human species
has faced throughout its existence [62, 63]. This elaborate
polymorphicnatureofHLAallelesenablesthemtorecognize
variousproteinfragmentsofpathogensandpresenttoTcells
for generation of appropriate immune responses. Among
these host genetic factors, HLA class I molecules, which
present peptides to cytotoxic T cells, have been shown to
exert profound inﬂuence over controlling the HIV-1. The
protective alleles, HLA-B∗57, -B∗27, and -B∗51, through
presentation of highly conserved HIV-1 epitopes to cytotoxic
T lymphocytes (CTL) and subsequent immunodominant6 Advances in Virology
immune response, drive formation of speciﬁc CTL escape
mutants, that are compromised in their replicative ﬁtness
[64–68]. These CTL escape mutants, depending on nature of
HLA-mediated immune pressure from subsequent hosts in
thetransmissionchain,maygeteitherﬁxedinthepopulation
or get reverted to their wild type form [38, 69]. Selection
pressure exerted by host on HIV-1 is discussed further under
the subsequent Section 4.
4.Host GeneticFactorsInﬂuence
HIV-1 Evolution
HIV-1 adapts to host immune pressure, and this is revealed
through studies of positively selected amino acid changes in
diﬀerent proteins of the virus [70–74]. An immunoinfor-
maticanalysisthatlookedatenvelopesequencesacrossclades
from varied geographical regions has indicated diﬀerences in
frequencyofpositiveselection(PS)sites,suggestingthatviral
clades prevalent in various geographically distinct parts of
the globe evolve in response to the characteristic immuno-
genetic proﬁle of the host population [70]. Evolutionary
p a t h w a y so fH I V - 1a p p e a rt ob ev a s tw i t ho c c u r r e n c eo f
positive selection sites not only in epitopes of CD4+ and
CD8+ T cells and antibodies, wherein HLA impacts pro-
foundly, but also in other regions which are likely to suﬀer
selection pressure via eﬀectors of innate arm of the immune
system such as KIR and HIV restriction factors TRIM5α,
APOBEC3G [75]. In contrast, HIV-2 that causes less severe
form of disease face signiﬁcant negative selection pressure
[76].
Several AIDS restriction genes have been identiﬁed [77,
78]. Among these HLA, killer-cell immunoglobulin-like
receptors(KIRs),chemokinereceptorsandintrinsic antiviral
factors like TRIM5α, APOBEC3 are known to exert substan-
tial inﬂuence over HIV/AIDS and aﬀect HIV-1 evolution.
TRIM5α, for example, has the ability to recognize the capsid
protein of the incoming virus and disassembling it upon
entry [79]. APOBEC3 proteins are another group of host
restriction factors that play a role in reducing viral infection,
includingHIV-1[80].Thesehostproteinsarecytidinedeam-
inases that catalyze the deamination of cytidine to uridine,
which results in guanosine to adenosine hypermutation in
the concerned opposite strand, favouring inactivation of
the virus [79, 81]. HIV-1 negates the antiviral eﬀects of
APOBEC3G (A3G) through its Vif (viral infectivity factor).
Viral infectivity factor promotes proteosomal degradation of
A3G in an incomplete fashion, as a result of which there
is generation of hypermutated viral population that could
still survive, aiding HIV-1 evolution and possibly favouring
emergence of drug resistant forms [82]. Fourati et al. [83]
showed that HIV patients exhibiting virological treatment
failure often possessed K22H point mutation in Vif, which
resulted in inability of Vif to counteract APOBEC3 proteins,
ultimately leading to G-to-A hypermutation in HIV. Several
other studies have also demonstrated role of APOBEC3 pro-
teinsinHIV-1evolution[84–87].Recently,studybyNorman
et al. [88] indicated that HIV-1 also employs viral protein
R (Vpr) to negate A3G antiviral properties by diminishing
the incorporation of uridines in the deamination process.
Interestingly, this act by Vpr results in favour of host as
DNA damage response pathway got triggered and NK cell-
activating ligands got expressed, making the virus vulnerable
to attack by NK cells [88]. Human tetherin also acts to
preventthespreadofHIV-1infectiontoothercells.Tetherin,
a cell surface host protein, is able to trap virions that are
being released from the surface of the infected cell [79, 89].
Diﬀerential adaptation of HIV-1 viruses to antiviral activity
oftetherinhasbeenrecentlyconﬁrmed.Yangetal.[90]dem-
onstrated that while Vpu of both group M and N HIV-1
viruses had activity against human tetherin, Vpu and Nef
from group O and P viruses lacked such anti-tetherin
a c t i v i t y .Av e r yr e c e n ts t u d yb yL i ue ta l .[ 91]r e p o r t e di d e n -
tiﬁcation of 114 intrinsic host factors with signiﬁcant ability
toinhibitHIV-1infectionandthisillustratesthetremendous
pressure HIV-1 is subjected to, upon entry into its host. It
could be inferred that various host genetic factors might
additively contribute to controlling the virus. The complex
HIV-1 host interactions are being dissected using genome-
wideandlarge-scalestrategiestomapvirus-hostinteractions
comprehensively [92].
4.1. HLA Leaves Footprints on HIV-1. The impact of HLA
diversity on HIV evolution has been documented in several
studies. Diﬀerent HLA alleles have been shown to be asso-
ciated with diﬀerent rates of HIV disease progression. For
example, patients who possess HLA-B∗27 and -B∗57 alleles
normallyhavelowviralloadsandprogresstoAIDSatamuch
slower rate, while those possessing HLA-B∗35 progress to
AIDS deﬁning illnesses rapidly [64]. HIV-1 is under pressure
from HLA-mediated CTL responses quite early in the
infection as CTL escape mutations have been shown to arise
as early as 14 days of postinfection [93]. CTL epitopes, are
reported to be more conserved compared to CD4+ Th e l p e r
and monoclonal antibody epitopes and this conservation
of CTL epitopes has been suggested as a host strategy to
constrain HIV-1 adaptation [94]. Evidence of HLA footprint
on HIV-1 genome is demonstrated by studies that have
investigated the mutation proﬁle of original infecting HIV-
1 strains. Leslie et al. [95] analyzed the mutation of clade B
and C HIV-1 in patients with HLA-B∗57/58:01 allele, which
areassociatedwithslowprogressiontoAIDS.Itwasobserved
that positively selected amino acids had accumulated and,
once transmitted to HLA-B∗57/B∗58:01 negative individu-
als, the virus reverted back to its wild-type form [95]. This
illustrates the ability of HLA alleles to drive the necessary
mutation in HIV, as part of controlling the infection. In
another study, the carriage of HLA-B∗57 allele in patients
infected with HIV-1 and its impact on viral control was
assessed. It was demonstrated that individuals expressing the
HLA-B∗57 allele controlled viremia without therapy at levels
<5000copies/mL of virus for upto 29 months, and a stronger
andbroaderresponsewasgeneratedbyHLA-B∗57allelethan
other HLA class I alleles [96]. A Swiss HIV cohort study,
that reported similar transcriptome proﬁle of CD4+ and
CD8+ T cells among rapid progressors and pathogenic SIV-
infected rhesus macaques, also found underrepresentationAdvances in Virology 7
of protective alleles and overrepresentation of risk alleles at
HLA loci in rapid progressors [97]. HLA selection pressure
on HIV-1 is so ﬁne-tuned that micropolymorphism seen
among subtypes of a particular allele could exert diﬀerential
pressure on virus. This phenomenon has been recently
demonstratedfortheHLA-B∗57alleles[98].Thesupportfor
extensiveHLAassociatedselectioninHIV-1isalsoevidentin
the recent study by Dong et al. [99], wherein they followed
a narrow-source HIV-1 outbreak, that occurred through
aplasmadonationschemeinaChinesevillageandfound24–
56% of the polymorphic sites across Gag, reverse transcrip-
tase, integrase, and Nef had HLA footprints. A comprehen-
sivegenomewideassociationanalysishasrevealedthatamino
acids at positions 67, 70, and 97 in HLA-B play a major role
in determining HIV-1 control, given their involvement in
peptide binding within the peptide binding groove [100].
HLA-Bloci, the most rapidly evolving class I region, con-
tains alleles that exert strong selection pressure over HIV-1
through their allele-restricted CD8+ T cell responses and
contributestoshapingofHIV-1evolution[101,102].HLA-B
might predominantly shape HIV and vice versa, a coevolu-
tion scenario [67, 101] as exempliﬁed by Red Queen Hypo-
thesis [103]. Also rapid selection for HLA alleles that protect
against HIV-1 infection has been found to correlate signiﬁ-
cantly with declining incidence of HIV-1 in an East African
sex worker cohort of Kenya, which suggests that natural
selection might eventually play a vital role in containing the
HIV-1 epidemic [104]. It may be plausible that mutome of
HIV and human is being shaped by each other in a very
delicate dynamic process of virus-human partnership.
Intrinsic and adaptive immunity might work synergisti-
cally to contain HIV-1. This can be inferred from the studies
that have dissected role of HLA and KIR compound geno-
types over HIV disease progression [105]. Further, recently
CTL escape mutations in Gag have been shown to enhance
sensitivity of HIV-1 to TRIM5α [106]. It is plausible that
HIV-1couldsuﬀeradoublewhammyattack-one,ﬁtnesscost
due to mutation in a highly conserved region and, second,
increased vulnerability to attack from TRIM5α.I no r d e r
to survive host immune pressure, which is predominantly
dictated by HLA, HIV mutates at speciﬁc epitopic region and
this escape variant to survive further without compromising
itsﬁtnessmightundergocompensatorymutationsinregions
away from the concerned epitope. Though HIV-1 mutates
rapidly as a stochastic process, its mutational strategies are
relatively predictable. The studies employing HIV-1-infected
identical twins suggested the presence of a relatively narrow
window period in HIV infection, wherein the immune
responses, viral evolution as well as disease progression are
somewhat reproducible and hence predictable [107–109].
Moreover, recently Dahirel et al. [110] have elegantly carried
out coordinate linkage analysis employing a physics con-
cept to highlight multidimensionally constrained regions of
HIV-1 proteome. They have identiﬁed HIV sectors that is,
distinct sets of amino acids whose mutations are collectively
coordinatedandindicatedthatamongtheﬁvesectorsofGag,
sector 3, which plays vital role in assemblage of multiprotein
structures for formation of HIV-1 capsid, is the most immu-
nologically vulnerable multidimensionally constrained and
also is the sector most targeted by elite controllers of HIV-
1, who harbour protective HLA alleles. These studies bear
potential clues for designing successful anti-HIV immuno-
gens. While role of HLA class I alleles in attenuating HIV-1 is
vastly studied and supported by several ﬁndings, part played
by HLA class II alleles has been scarcely investigated [64,
111, 112]. A recent study that investigated the correlation
betweenHLAclassIIallelesandinvitroreplicationcapacities
of recombinant viruses encoding Gag-protease from HIV-1
subtype C infected chronic patients failed to detect any asso-
ciation of alleles with lower ﬁtness [113]. However, earlier
studies have demonstrated potential role of HLA class II
alleles in exerting selection pressure on HIV-1 [114, 115].
More studies are warranted, given the reported signiﬁcant
genetic associations of alleles belonging to HLA-DR, -DQ,
and -DP loci with HIV infection and disease [64, 111, 116–
120] ,t od e l i n e a t ed e g r e eo fi m m u n ep r e s s u r ee x e r t e db y
diﬀerent HLA class II alleles, the players in generating the
essential T helper cell responses. T-cell-based vaccine strate-
gies that couldaddress HIV-1 diversity issues better are being
tested [121, 122].
4.2. KIR Footprints on HIV-1. Killer-cell immunoglobulin-
like receptor (KIR) encoding genes are located on chromo-
some 19, and their major role is to control the activation
or inhibition of Natural Killer (NK) cells, which belong to
the innate arm of the immune system. KIRs are quite poly-
morphic, and thus they are able to generate a diverse res-
ponse to a variety of pathogens. KIRs mediate their eﬀects
using HLA molecules as ligands [123, 124].
HIV-1, like other viruses, down-regulate HLA class I
molecules, speciﬁcally HLA-A and -B, and hence escapes
from those HLA-mediated CTL eﬀectors. However, in order
to escape attack by NK cells, which destroys target cells
lacking expression of HLA class I molecules, HIV-1 avoids
downregulating KIR-interacting HLA-C or the nonclassical
HLA-E molecules [125]. KIRs are known to impact HIV-1
disease outcome both independently and synergistically
throughitsinteractionwithHLAligands[126,127].Arecent
studyhasdemonstratedroleofcopynumbervariationinKIR
genes in inﬂuencing HIV-1 control [128]. Alter et al. [129]
have shown that HIV-1 evades NK cell-mediated immune
response by selecting for viral variants that modulate recog-
nition of infected cells by KIR to their advantage. Specif-
ically they identiﬁed 22KIR-associated polymorphisms in
HIV-1 from a cohort of 91 untreated chronically HIV-1-
infected patients. HIV-1 viruses with Vpu (71M/74H) (Env
(17W/20M)), Gag (138I), and Nef (9K) were found to be
signiﬁcantly enriched in individuals possessing KIR2DL2,
and these KIR footprints enhanced the binding of inhibitory
KIR to infected cells, due to which inhibition of NK cell
function ensues and HIV-1 escapes attack [129].
5. Problems Posed byHIV-1 Diversity
5.1.SearchforaBroadlyCross-ReactiveAnti-HIVNeutralizing
Antibody. HIV-1 diversity is one among several challenges
that needs to be addressed while attempting to design an8 Advances in Virology
eﬀective anti-HIV vaccine. Generating broadly neutralizing
antibodies (bnAbs) that can eﬀectively inactivate or neutral-
ize HIV variants remains elusive [130]. Broadly neutralizing
antibodies are rare and undetectable in most HIV-1-infected
individuals. Several hypotheses exist that attempt to explain
the rarity of bnAbs. For example, one reason that has been
proposed is that highly immunogenic epitopes may trigger
nonneutralizing antibodies instead of activating required
speciﬁcresponses[131,132].However,nonneutralizinganti-
bodies could be functional against HIV-1, as observed in
study subjects of RV144 Trial [133], and have potential to
mediate protection against HIV-1. Studies have also shown
that antibodies sometimes select for escape mutations
[134, 135]. There are four regions of HIV-1 Env that could
serve as targets for bnAbs: gp120 CD40 binding site, quater-
nary V2/V3 loop epitopes, gp41 Membrane proximal exter-
nal region (MPER), and Env carbohydrates [132]. Human
immunoglobulin, VRC01, is capable of neutralizing 90% of
the HIV-1 isolates [136]. Recent studies have delineated both
evolutionary course and nature of VRC01-like antibodies
[137, 138], and this knowledge has opened up new avenues
for strategies to attack HIV-1 better.
5.2. Correlates of Protection Obscured by HIV-1 Evolution.
Certain host genotypes known to be favourable prior to ART
m i g h tt u r no u tt oe x e r tad e t r i m e n t a lo rn e u t r a le ﬀect upon
initiation of treatment. This intriguing observation is being
reported frequently, and yet the mechanism underlying the
association is unclear. Rauch et al. [139] reported that
Bw4 homozygosity, associated with protection in untreated
patients, predicted impaired CD4 T-cell recovery upon com-
mencement of combination ART. Another study revealed
strong association of HLA-B∗57:01 and -B∗58:01, both
exhibiting Bw4 motifs, with failure to control HIV repli-
cation following HAART initiation [140]. While HAART
exhibitsthepotentialtosuppressHIVreplicationprofoundly
irrespective of the genotype of the individual, documented
association of speciﬁc highly protective alleles with diﬀeren-
tial outcome over treatment may have an unidentiﬁed func-
tional immunological basis and warrants extensive investi-
gation. Antiretroviral therapy-induced selection pressure on
polcouldleadtogenerationofHIV-1quasispecieswithsigni-
ﬁcant changes in epitope proﬁle, including loss of protective
epitopes. Furthermore, HLA-KIR interaction might con-
tribute to outcome of ART [139, 140] and may explain the
conundrum of what is good before ART is not so after ART.
HLA-B∗51 has been associated with protection against
HIV-1 in Asian population [67, 68]. This allele has been able
to confer a multilayered defence against HIV/AIDS through
presentationofhighlyconservedimmunodominant epitopes
inGagregion,thatrarelyundergomutation,and,ifatallgets
mutated, it is only at the cost of ﬁtness. However, it has been
noted that, over a period of time, at population level, the
circulating viruses, as they evolve, tend to lose the epitopes
targeted by the protective alleles such as HLA-B∗51 [67,
68, 141], such that documented protective association is
obscured and these evolutionary strategies by which HIV
changes its genomic/proteomic landscape to stay ahead, pose
tremendous challenge for scientists as they search for true
correlates of protection against HIV/AIDS and venture into
developing a stable and eﬀective intervention-prophylactic/
therapeutic vaccine [142, 143]. Interestingly, a mathematical
modeling study has predicted that the rate of generation of
escape mutants and the transmission of escape mutants may
have only a weak impact on the epidemic outcome over the
ﬁrst 25 years after the introduction of a nonsterilizing anti-
HIV vaccine [144]. However, search for a sterilizing vaccine
for HIV/AIDS, a holy grail, remains vital aim in ﬁght against
HIV [145].
Characterizing immunological proﬁle in both elite con-
trollers and HIV-exposed seronegatives could lead to bet-
ter understanding of correlates of protection [143, 146–
151]. Additionally, understanding immunobiological basis
of benign nature of disease induced by HIV-2 can provide
clues into virus-host interaction and aid in tackling HIV-1.
Expanding HIV-1 diversity might pose problems at diagnos-
tic level given its impact on viral load testing assays [152].
6. Scope of ART inHIV-1 Control
According to UNAIDS world AIDS day report 2011, at least
6.6million people in low- and middle-income countries are
receiving HIV treatment and this has resulted in prevention
of 2.5million AIDS deaths since 1995 [2]. Also ART prevents
infection, as it reduces viral load and infectiousness of an
infected individual [153]. While this is an encouraging sign
towards combating the HIV/AIDS epidemic, it is to be
emphasized that current drugs in the prescribed regimen are
unabletoattackanderadicatetheviruseshidinginreservoirs
such as seminal vesicles [154] and tissue macrophages of
HIV infected patients [155]. Given the evidences that suggest
continual on-going replication of HIV-1 in such reservoirs
[156,157],itisplausiblethatquasispeciesthatareimmuneto
current combination ART drugs can emerge upon treatment
interruption. HIV-1 occupies variety of anatomic compart-
m e n t ss u c ha sc e n t r a ln e r v o u ss y s t e m( C N S ) ,g u t - a s s o c i a t e d
lymphoid tissue (GALT), and genitourinary tract [158, 159].
The CNS, endowed with blood-brain-barrier, is a pharmac-
ologically “privileged” site, and the virus inside CNS thus
gets shielded from attack by some ART drugs [159–161].
Genotypic diversity of HIV-1 is not uniform across diﬀerent
compartments [162]. This can be inferred by the fact that
majorityvariantseeninbloodisnotalwayssoinsemen[163,
164]. Further, env sequences from blood and male genital
tract compartments diﬀer [165]. Venturi et al. [166]h a v e
observed diﬀerent drug resistance mutation proﬁle between
HIV-1 isolates from cerebrospinal ﬂuid and plasma in
patients under nonsuppressive ART drug regimens. Indeed
selective drug pressure has been shown to result in multiple
drug-resistant HIV-1 quasispecies [167]. Viral rebound in
patients who cease to continue with the ART is an added
concern [168].
A recent study that evaluated the correlation of preexist-
ing drug-resistant HIV-1 minority variants with risk of ﬁrst-
line nonnucleoside reverse transcriptase inhibitor (NNRTI)Advances in Virology 9
based antiretroviral virologic failure, by reviewing 10 dif-
ferent studies, has suggested signiﬁcant association of low-
frequency drug resistance mutations with a dose-dependent
increased risk of failure to control the virus [169]. Another
causeforconcernisthediﬀerentialpersistenceoftransmitted
HIV-1 drug resistance mutation classes as reported by Jain
et al. [170], wherein they indicated long-term persistence
of NNRTI and protease inhibitor mutations which might
facilitate person-to-person propagation. Adherence to drug
regimen among HIV-1 patients is threatened by the fact
thatcertainprescribed combination ARTdrugs couldinduce
unfavourable side eﬀects among patients with speciﬁc geno-
types. For instance, hypersensitivity reactions (HSRs) are
seeninHLA-B∗57:01positiveHIV-1patientsreceivingAba-
cavir (ABC), an nucleoside reverse transcriptase inhibitor
(NRTI) drug [171]. While there are similar eﬀects docu-
mented for other ART drugs [172], the association of ABC
with HSR in HLA-B∗57:01 patients is robust enough that
screening for this allele has been made routine prior to
prescription of combination ART regimen containing ABC
[173]. More insights into pathophysiology of drug-induced
HSR in HIV patients can ensure case-speciﬁc recommenda-
tion of combination ART drugs, averting compliance issues
and emergence of drug resistant viral population. He et al.
[174], by conducting a 7-year follow-up study on 437HIV-
infectedChinesepatientsundergoingHAART,suggestedthat
two NRTIs and one NNRTI regimens could persistently sup-
press HIV viremia and enhance CD4+ T-cell population with
good safety and tolerance. The study also reported 19.2%
of the participants changed to other ﬁrst-line drug due to
drug-related side eﬀects and 10.2% switched to second-line
regimens because of viral resistance. As UNAIDS and WHO
advocate Treatment 2.0 [175], many such prospective studies
analyzing outcome of HAART regimens are essential and
antiretroviral pharmacovigilance [176] will attain greater
importance.
HIV drug resistance could be either acquired or trans-
mitted. According to recent initial survey conducted in low-
and middle-income countries, WHO has reported acquired
HIV drug resistance rate to be 6% while 3.7% rate for the
transmitted HIV drug resistance [177]. The 2009 Surveil-
lanceDrugResistanceMutation(SDRM)listhasindicated93
mutations including 34NRTI-resistance mutations (at 15RT
positions), 19NNRTI-resistance mutations (at 10RT posi-
tions), and 40PI-resistance mutations (at 18protease posi-
tions), and this suggests the vast number of mutations linked
to antiretroviral drug resistance [178] .T h eﬁ t n e s sl a n d s c a p e
ofHIV-1RTandproteasehasbeenshowntobeunderstrong
epistasis [179]. Epistasis refers to a situation wherein action
of one genetic locus masks the allelic eﬀects at another locus,
and the locus thus masked is referred to be “hypostatic” to
the other locus [180, 181]. This phenomenon of epistatic
interaction complicates comprehensive understanding of
viral variants and their relationship to drug resistance. Even
though today there are more than 20 diﬀerent antiretroviral
drugs to treat HIV-infected patients, a major global public
health concern is the emergence of new strains that develop
resistance to these drugs and subsequent transmission to
other hosts [176].
Antiretroviral therapy has been quite successful which
can be attributed to its ability to control HIV replication
and preserve optimal CD4+ T helper cell population, due to
which many of the opportunistic infections associated with
abnormal low CD4+ T-cell counts are averted. However,
tuberculosis (TB), caused by Mycobacterium tuberculosis,c a n
occur at any stage of the disease, irrespective of CD4+ T-cell
counts,inHIV-1-infectedpatients[182]andposesatremen-
dous public health challenge in regions plagued by dual
epidemic of HIV and TB. HIV-associated TB and hepatitis
complicate the clinical management of individuals suﬀering
from such coinfections, with potential for development of
immune reconstitution inﬂammatory syndrome and drug-
drug interactions are not clearly understood [183, 184].
HIV-1 latency presents challenges for the attempts
directed at eradicating it. The half-life of the latent, repli-
cation-competent HIV-1 in resting CD4+ T cells is roughly
six months, which necessitates compliance to eﬀective ART
regimen for several years to clear the virus from reservoir
[157]. Strategies are being contemplated to activate the HIV
residing in latent reservoirs, in such a manner that does not
allow wide-spread infection of uninfected cells [185, 186],
and, in this regard, current and future ART drugs could play
vital role in eradicating resilient virus.
7. Conclusion
The studies on biology of HIV-1 variation by characterizing
emerging quasispecies population carries prognostic value as
they impact rate of development of AIDS deﬁning illnesses
[187]a sw e l la se ﬀectiveness of therapy [188]. Diﬀerent
recombinant forms of HIV-1 emerge, and they are seen to
predominate in particular environments [189–191]. Given
this scenario, more comprehensive epitope mapping studies
with focus on CTL epitope escape mutants of CRFs, in addi-
tion to characterizing epitope proﬁle of major HIV-1 clades,
are warranted, and such ﬁndings will augment the eﬀorts to
curb spread of HIV-1, a virus nonpareil in medical history
due to its ever elusive tricks inﬂicting damage to global
health. The advent of HAART has made HIV/AIDS a life-
threatening fatal into a potential chronic disease. However,
HIV patients under long-term treatment are likely to have
higher risk for medical complications like heart, liver, and
neurodegenerative diseases, and hence there is an increasing
need to deal with these additional health issues eﬀectively
[192].Avaccinethatcouldelicitsterilizingimmunityagainst
HIV/AIDS is much desired. Recent ﬁndings, RV144 Trial,
with its ﬁnding that prime-boost vaccine combination of
ALVAC-HIV and AIDSVAX B/E oﬀering 39.2% protection
against HIV [193]; a 1% tenofovir gel inhibiting HIV sexual
transmission by 39% [194]; a person with 12 years of infec-
tion considered to be cured of HIV as part of ﬁghting acute
myeloid leukemia via haematopoietic stem cell transplanta-
tion from a CCR5 32 homozygous donor [195–197]a r e
quite encouraging and serve as testimonial to the fact that
HIV-1 can be conquered through further research which
includes dissecting mechanisms of underlying protection
and moving forward with those anti-HIV immunobiological
clues [198–201]. While debate on attenuation of HIV-1, as it10 Advances in Virology
evolves continues [36, 37, 202, 203], focused and concerted
eﬀorts by scientists, employing multidisciplinary approaches
to attack HIV, might enable achieving UNAIDS mission
of “zero new HIV infections, zero discrimination and zero
AIDS-related deaths” earlier.
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